Prolactin response to aripiprazole

Psychiatry and Clinical Neurosciences

Volumn 66, Issue 6, 2012, Pages 518-524

  Nagai, Goyo ^a   Mihara, Kazuo ^a   Nakamura, Akifumi ^a   Suzuki, Takeshi ^a   Nemoto, Kenji ^a   Kagawa, Shoko ^a   Ohta, Ikuya ^b   Arakaki, Hajime ^b   Kondo, Tsuyoshi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Arakaki Hospital   (Japan)

Author keywords

aripiprazole; CYP2D6; DRD2; prolactin; sex

Indexed keywords

ARIPIPRAZOLE; BIPERIDEN; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; FLUNITRAZEPAM; PROLACTIN; DNA; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; ADULT; BLOOD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INTERACTION; GENETICS; JAPAN; LUMINESCENCE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; REGRESSION ANALYSIS; SEXUAL DEVELOPMENT;

ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; JAPAN; LUMINESCENCE; MALE; MIDDLE AGED; PIPERAZINES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PROLACTIN; QUINOLONES; RECEPTORS, DOPAMINE D2; REGRESSION ANALYSIS; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 84867518025     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2012.02391.x     Document Type: Article

References (32)

1. Shapiro DA, Renock S, Arrington E, et al,. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-1411. (Pubitemid 41070874)
2. Harrison TS, Perry CM,. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64: 1715-1736. (Pubitemid 39128008)
3. Kerwin R, Millet B, Herman E, et al,. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study. Eur. Psychiatry 2007; 22: 433-443. (Pubitemid 47600616)
4. Hanssens L, L'Italien G, Loze JY, et al,. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: Results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008; 8: 95.
5. Gründer G, Carlsson A, Wong DF,. Mechanism of new antipsychotic medications. Occupancy is not just antagonism. Arch. Gen. Psychiatry 2003; 60: 974-977. (Pubitemid 37222078)
6. Mihara K, Nagai G, Nakamura A, et al,. Improvement in antipsychotic-induced hyperprolactinemia with the addition of aripiprazole in schizophrenic patients. Clin. Neuropharmacol. Ther. 2010; 1: 1-5.
7. Yasui-Furukori N, Saito M, Nakagami T, et al,. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog. Neuropsychopharmacol Biol. Psychiatry 2010; 34: 537-540.
8. Yasui N, Kondo T, Otani K, et al,. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol. Toxicol. 1998; 82: 153-156. (Pubitemid 28131373)
9. Yasui-Furukori N, Kondo T, Suzuki A, et al,. Effects of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol. Schizophr. Res. 2001; 52: 139-142. (Pubitemid 32947058)
10. Jönsson EG, Nöthen MM, Grünhage F, et al,. Polymorphism in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 1999; 4: 290-296. (Pubitemid 29292183)
11. 2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology 2000; 149: 246-250. (Pubitemid 30262338)
12. Mihara K, Suzuki A, Kondo T, et al,. Relationship between Taq1 A dopamine receptor (DRD2) polymorphism and prolactin response to bromperidol. Am. J. Med. Genet. 2001; 105: 271-274. (Pubitemid 32410901)
13. Young RM, Lawford BR, Barnes M, et al,. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2 A1 allele. Br. J. Psychiatry 2004; 185: 147-151. (Pubitemid 39061458)
14. Aklillu E, Kalow W, Endrenyi L, Harper P, Miura J, Ozdemir V,. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet. Genomics 2007; 17: 989-993. (Pubitemid 350293798)
15. 2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet. Genomics 2009; 19: 373-382.
16. Zhang XR, Zhang ZJ, Zhu RX, Yuan YG, Jenkins TA, Reynolds GP,. Sexual dysfunction in male schizophrenia: Influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics 2011; 12: 1127-1136.
17. Sakuyama K, Sasaki T, Ujiie S, et al,. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos. 2008; 36: 2460-2467.
18. Ozdemir V, Bertilsson L, Miura J, et al,. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revised. Pharmacogenet. Genomics 2007; 17: 339-347. (Pubitemid 46608541)
19. Kubo M, Koue T, Maune H, Fukuda T, Azuma J,. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: Influence of CYP2D6 polymorphism. Drug Metab. Pharmacokinet. 2007; 22: 358-366.
20. Kubo M, Mizooku Y, Hirao Y, Osumi T,. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J. Chromatogr. B 2005; 822: 294-299. (Pubitemid 40994064)
21. Grandy DK, Zhang Y, Civelli O,. PCR detection of the TaqA RFLP at the DRD2 locus. Hum. Mol. Genet. 1993; 2: 2197. (Pubitemid 24003431)
22. Arinami T, Gao M, Hamaguchi H, Toru M,. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 1997; 41: 577-582. (Pubitemid 27142107)
23. Steen VM, Andreassen OA, Daly AK, et al,. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5: 215-223.
24. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K,. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 2000; 50: 31-34. (Pubitemid 30416968)
25. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M,. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 1994; 46: 452-459. (Pubitemid 24296678)
26. Kirschbaum KM, Müller MJ, Malevani J, et al,. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J. Biol. Psychiatry 2008; 9: 212-218.
27. 18F] fallypride PET study. Am. J. Psychiatry 2008; 165: 988-995.
28. Suzuki T, Mihara K, Nakamura A, et al,. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther. Drug Monit. 2011; 33: 21-24.
29. Kwon JS, Kim E, Kang DH, et al,. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur. Neuropsychopharmacol. 2008; 18: 897-907.
30. Iranmanesh A, Mulligan T, Veldhuis JD,. Mechanisms subserving the physiological nocturnal relative hypoprolactinemia of healthy older men: Dual decline in prolactin secretary burst mass and basal release with preservation of pulse duration, frequency, and interpulse interval- a General Clinical Research Center study. J. Clin. Endocrinol. Metab. 1999; 85: 1083-1090. (Pubitemid 29138247)
31. Ufearo CS, Orisakwe OE,. Restoration of normal sperm characteristics in hypoprolactinemia infertile men treated with metoclopramide and exogenous human prolactin. Clin. Pharmacol. Ther. 1995; 58: 354-359.
32. Houston J, Dharia S, Bishop JR, et al,. Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Psychiatry Res. 2011; 187: 74-79.